Author:
Mohamed-Yassin Mohamed-Syarif,Rosman Norhidayah,Kamaruddin Khairatul Nainey,Miptah Hayatul Najaa,Baharudin Noorhida,Ramli Anis Safura,Abdul-Razak Suraya,Lai Nai Ming,
Abstract
AbstractDyslipidaemia is an established cardiovascular risk factor. This study aimed to determine the pooled prevalence of dyslipidaemia in Malaysian adults. A systematic review and meta-analysis of all cross-sectional, longitudinal observational studies which reported the prevalence of elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), triglycerides (TG), and reduced high-density lipoprotein cholesterol (HDL-c) in adults 18 years old and older, was conducted. A comprehensive search of PubMed and Cochrane Central Register of Controlled Trials (which included Medline, EMBASE and major trial registers) from inception to October 18, 2022, was performed. Risk-of-bias was evaluated using the Johanna-Briggs Institute Prevalence Critical Appraisal Tool, while certainty of evidence was assessed using an adapted version of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Random-effects meta-analyses were performed using MetaXL. This report follows the PRISMA reporting guidelines. The protocol was registered with PROSPERO (CRD42020200281). 26 556 studies were retrieved and 7 941 were shortlisted initially. From this, 70 Malaysian studies plus two studies from citation searching were shortlisted; 46 were excluded, and 26 were included in the review (n = 50 001). The pooled prevalence of elevated TC (≥ 5.2 mmol/L), elevated LDL-c (≥ 2.6 mmol/L), elevated TG (≥ 1.7 mmol/L), and low HDL-c (< 1.0 mmol/L in men and < 1.3 mmol/L in women) were 53% (95% CI 39–67%, I2 = 100%), 73% (95% CI 50–92%, I2 = 100%), 36% (95% CI 32–40%, I2 = 96%), and 40% (95% CI 25–55%, I2 = 99%), respectively. This review found that the prevalence of all dyslipidaemia subtypes is high in Malaysian adults. Ongoing efforts to reduce cardiovascular diseases in Malaysia should integrate effective detection and treatment of dyslipidaemia.
Publisher
Springer Science and Business Media LLC
Reference86 articles.
1. Health Technology Assessment Unit. Clinical Practice Guidelines on Management of Dyslipidaemia (Ministry of Health Malaysia, 2017).
2. Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267–1278. https://doi.org/10.1016/S0140-6736(05)67394-1 (2005).
3. Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532–2561. https://doi.org/10.1016/S0140-6736(16)31357-5 (2016).
4. Fletcher, R., Fletcher, S. & Fletcher, G. S. Clinical Epidemiology: The Essentials 5th edn. (Lippincott Williams & Wilkins, 2014).
5. Migliavaca, C. B. et al. Quality assessment of prevalence studies: A systematic review. J. Clin. Epidemiol. 127, 59–68. https://doi.org/10.1016/j.jclinepi.2020.06.039 (2020).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献